Allogenic stem cell transplant can cure high-risk CLL
Although most cases of small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) are considered indolent and can be effectively treated with chemotherapy, some patients do not respond to traditional treatments. These patients are considered high-risk, and in them the disease can be fatal within just a few years.
To address this group of patients, the German CLL Study Group (GCLLSG) undertook a multicenter (16) clinical phase II study that included 90 patients with high-risk SLL/CLL. In this so-called CLL3X trial, all patients received pre-transplant chemotherapy followed by an allogenic stem cell transplant. Findings indicated that, at a median follow-up of four years, approximately half of the cohort was disease-free, leading the study's authors to conclude that this treatment has the potential to cure some patients in the high-risk group.
TREATMENT TYPE
Allogenic stem cell transplant. In this treatment, the patient receives stem cells from a matching donor.
WHERE WAS THIS RESEARCH PUBLISHED?
Online in the journal Blood.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
